stoxline Quote Chart Rank Option Currency Glossary
  
United Therapeutics Corporation (UTHR)
287.59  5.73 (2.03%)    06-13 16:00
Open: 280.29
High: 288.35
Volume: 434,593
  
Pre. Close: 281.86
Low: 279.31
Market Cap: 12,759(M)
Technical analysis
2024-06-13 4:46:59 PM
Short term     
Mid term     
Targets 6-month :  336.79 1-year :  393.37
Resists First :  288.35 Second :  336.79
Pivot price 275.32
Supports First :  271.08 Second :  260.41
MAs MA(5) :  279.09 MA(20) :  275.13
MA(100) :  242.04 MA(250) :  234.31
MACD MACD :  6 Signal :  6.1
%K %D K(14,3) :  87.1 D(3) :  78
RSI RSI(14): 73.7
52-week High :  288.35 Low :  208.61
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ UTHR ] has closed Bollinger Bands are 12.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 288.38 - 289.38 289.38 - 290.3
Low: 276.43 - 277.72 277.72 - 278.9
Close: 285.52 - 287.34 287.34 - 289.01
Company Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Headline News

Thu, 13 Jun 2024
Parkman Healthcare Partners LLC Has $35.52 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Thu, 13 Jun 2024
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market - Simply Wall St

Thu, 13 Jun 2024
United Therapeutics (NASDAQ:UTHR) Price Target Increased to $350.00 by Analysts at Wells Fargo & Company - Defense World

Thu, 13 Jun 2024
United Therapeutics Co. (NASDAQ:UTHR) Holdings Lifted by Comerica Bank - Defense World

Tue, 11 Jun 2024
United Therapeutics CEO Rothblatt sells over $1.98 million in company stock By Investing.com - Investing.com

Fri, 07 Jun 2024
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term - Zacks Investment Research

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 44 (M)
Shares Float 41 (M)
Held by Insiders 1.8 (%)
Held by Institutions 104.2 (%)
Shares Short 3,770 (K)
Shares Short P.Month 4,320 (K)
Stock Financials
EPS 21.12
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 120.76
Profit Margin 42 %
Operating Margin 52.5 %
Return on Assets (ttm) 12.2 %
Return on Equity (ttm) 20 %
Qtrly Rev. Growth 33.7 %
Gross Profit (p.s.) 0
Sales Per Share 56.34
EBITDA (p.s.) 29.52
Qtrly Earnings Growth 27 %
Operating Cash Flow 980 (M)
Levered Free Cash Flow 579 (M)
Stock Valuations
PE Ratio 13.61
PEG Ratio 1.1
Price to Book value 2.38
Price to Sales 5.1
Price to Cash Flow 13.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android